CytomX Therapeutics (CTMX) Reports In-Line Q2 EPS

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.37), in-line with the analyst estimate of ($0.37). Revenue for the quarter came in at $18.17 million versus the consensus estimate of $18.11 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen